VA NEPHRON-D 研究:尿液生物标志物与临床试验中的急性肾损伤表型分析
VA NEPHRON-D 子研究纳入 707 例患者,中位随访 2.2 年,比较联合与单药 RAAS 阻断组尿液生物标志物差异。联合组血清肌酐定义 AKI 发生率 20.7% 高于单药组 12.7%(RR 1.64,95%CI 1.16-2.30)。尽管 AKI 风险增加,联合组 12 个月尿液生物标志物未升高或降低,提示生物标志物可能有助于进一步刻画临床试验中的肾损伤。
要点
- 联合 RAAS 阻断组 AKI 发生率 20.7% 高于单药组 12.7%(RR 1.64,95%CI 1.16-2.30)。
- 联合组 12 个月尿白蛋白排泄率较单药组降低 24%(RR -24%,95%CI -37% 至 -8%,Padj=0.02)。
- 联合组 12 个月尿 YKL-40 较单药组降低 40%-44%(95%CI -58% 至 -25%,Padj<0.001)。
核心结论
- 尽管血清肌酐定义 AKI 风险增加,联合 RAAS 抑制剂治疗与 12 个月尿液生物标志物未升高或降低相关,提示尿液生物标志物可能有助于进一步刻画临床试验中的肾损伤。
研究设计与样本
- VA NEPHRON-D 试验的子研究,纵向分析,纳入 707 例参与者,中位随访 2.2 年。
主要发现
- 联合组 AKI 发生率 20.7% vs 单药组 12.7%(RR 1.64,95%CI 1.16-2.30)。
- 12 个月时联合组 vs 单药组:MCP-1 RR -3%(95%CI -13% 至 9%,Padj=0.8);KIM-1 RR -10%(95%CI -20% 至 1%,Padj=0.2);EGF RR -7%(95%CI -12% 至 -1%,Padj=0.08)。
- 12 个月时联合组 vs 单药组:白蛋白尿 RR -24%(95%CI -37% 至 -8%,Padj=0.02);YKL-40 RR -40% 至 -44%(95%CI -58% 至 -25%,Padj<0.001)。
- 汇总 meta 分析显示干预组白蛋白尿降低见于 3 项试验,其他生物标志物轨迹相似。
临床怎么用
- 在临床试验中,血清肌酐单独定义 AKI 可能不足以完整反映肾损伤,尿液生物标志物可作为血清肌酐的辅助指标。
局限性
- 生物标志物测量仅限 2 个时间点,且独立于 AKI 事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Urinary biomarkers of injury, inflammation, and repair may help phenotype acute kidney injury (AKI) observed in clinical trials. We evaluated the differences in biomarkers between participants randomized to monotherapy or to combination renin-angiotensin-aldosterone system (RAAS) blockade in VA NEPHRON-D, where an increased proportion of observed AKI was acknowledged in the combination arm. STUDY DESIGN: Longitudinal analysis. SETTING & PARTICIPANTS: A substudy of the VA NEPHRON-D trial. PREDICTOR: Primary exposure was the treatment arm (combination [RAAS inhibitor] vs monotherapy). AKI is used as a stratifying variable. OUTCOME: Urinary biomarkers, including albumin, EGF (epidermal growth factor), MCP-1 (monocyte chemoattractant protein-1), YKL-40 (chitinase 3-like protein 1), and KIM-1 (kidney injury molecule-1). ANALYTICAL APPROACH: Biomarkers measured at baseline and at 12 months in trial participants were compared between treatment groups and by AKI. AKI events occurring during hospitalization were predefined safety end points in the original trial. The results were included in a meta-analysis with other large chronic kidney disease trials to assess global trends in biomarker changes. RESULTS: In 707 participants followed for a median of 2.2 years, AKI incidence was higher in the combination (20.7%) versus the monotherapy group (12.7%; relative risk [RR], 1.64 [95% CI, 1.16-2.30]). Compared with the monotherapy arm, in the combination arm the urine biomarkers at 12 months were either unchanged (MCP-1: RR, -3% [95% CI, -13% to 9%], Padj=0.8; KIM-1: RR, -10% [95% CI, -20% to 1%], Padj=0.2; EGF, RR-7% [95% CI, -12% to-1%], Padj=0.08) or lower (albuminuria: RR, -24% [95% CI, -37% to-8%], Padj=0.02; YKL: RR, -40% to-44% [95% CI, -58% to-25%], Padj<0.001). Pooled meta-analysis demonstrated reduced albuminuria in the intervention arm across 3 trials and similar trajectories in other biomarkers. LIMITATIONS: Biomarker measurement was limited to 2 time points independent of AKI events. CONCLUSIONS: Despite the increased risk of serum creatinine-defined AKI, combination RAAS inhibitor therapy was associated with unchanged or decreased urinary biomarkers at 12 months. This suggests a possible role for kidney biomarkers to further characterize kidney injury in clinical trials. PLAIN-LANGUAGE SUMMARY: The VA NEPHRON-D trial investigated inhibition of the renin-angiotensin-aldosterone system (RAAS) hormonal axis on kidney outcomes in a large population of diabetic chronic kidney disease patients. The trial was stopped early due to increased events of serum creatinine-defined acute kidney injury in the combination therapy arm. Urine biomarkers can serve as an adjunct to serum creatinine in identifying kidney injury. We found that urinary biomarkers in the combination therapy group were not associated with a pattern of harm and damage to the kidney, despite the increased number of kidney injury events in that group. This suggests that serum creatinine alone may be insufficient for defining kidney injury and supports further exploration of how other biomarkers might improve identification of kidney injury in clinical trials.
引用
- Kiernan EA, Hu D, Philbrook HT, et al. Urinary Biomarkers and Kidney Injury in VA NEPHRON-D: Phenotyping Acute Kidney Injury in Clinical Trials. Am J Kidney Dis. 2023. PMID: 37726051. doi:10.1053/j.ajkd.2023.07.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。